整合血液与尿液生物标志物识别急性肾损伤亚表型及其与长期结局的关联
该多中心队列研究纳入769例住院急性肾损伤(AKI)患者及769例匹配无AKI患者,采用29项临床、血浆和尿液生物标志物参数,通过潜在类别分析和k均值聚类识别出2种AKI亚表型。校正人口学、医院层面因素及KDIGO分期后,第2类亚表型长期主要不良肾脏事件(MAKE)风险高于第1类(校正HR 1.41,95%CI 1.08-1.84,P=0.01)。
要点
- 潜在类别分析和k均值聚类均识别出2种AKI亚表型(第1类和第2类)。
- 第2类亚表型长期MAKE风险高于第1类,校正HR 1.41(95%CI 1.08-1.84,P=0.01)。
- 区分两类亚表型最重要的变量为炎症和上皮细胞损伤的血浆及尿液生物标志物。
核心结论
- 识别出2种分子水平不同的AKI亚表型,其长期结局风险不同,且独立于现行AKI风险分层标准。
- 未来识别AKI亚表型可能有助于将治疗与潜在病理生理机制关联,以预防AKI后长期后遗症。
研究设计与样本
- 多中心队列研究,纳入2009年12月至2015年2月ASSESS-AKI研究中769例住院AKI成人患者,并匹配769例无AKI患者。
- 采用潜在类别分析和k均值聚类对29项临床、血浆和尿液生物标志物参数进行分析。
- 采用Kaplan-Meier曲线和Cox比例风险模型分析AKI亚表型与MAKE的关联。
主要发现
- 769例AKI患者中,潜在类别分析和k均值聚类均识别出2种不同的AKI亚表型(第1类和第2类)。
- 中位随访4.7年,第2类亚表型长期MAKE风险高于第1类(校正HR 1.41,95%CI 1.08-1.84,P=0.01),校正因素包括人口学、医院层面因素及KDIGO AKI分期。
- 第2类亚表型MAKE风险较高由长期慢性肾脏病进展和透析风险较高所解释。
- 区分第1类和第2类最重要的变量为炎症和上皮细胞损伤的血浆及尿液生物标志物;血清肌酐在29项变量中区分两类亚表型的排名为第20位。
局限性
- 缺乏同时采集血液和尿液样本的住院AKI成人患者且具有长期结局的重复队列。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Acute kidney injury (AKI) is a heterogeneous clinical syndrome with varying causes, pathophysiology, and outcomes. We incorporated plasma and urine biomarker measurements to identify AKI subgroups (subphenotypes) more tightly linked to underlying pathophysiology and long-term clinical outcomes. STUDY DESIGN: Multicenter cohort study. SETTING & PARTICIPANTS: 769 hospitalized adults with AKI matched with 769 without AKI, enrolled from December 2009 to February 2015 in the ASSESS-AKI Study. PREDICTORS: 29 clinical, plasma, and urinary biomarker parameters used to identify AKI subphenotypes. OUTCOME: Composite of major adverse kidney events (MAKE) with a median follow-up period of 4.7 years. ANALYTICAL APPROACH: Latent class analysis (LCA) and k-means clustering were applied to 29 clinical, plasma, and urinary biomarker parameters. Associations between AKI subphenotypes and MAKE were analyzed using Kaplan-Meier curves and Cox proportional hazard models. RESULTS: Among 769 AKI patients both LCA and k-means identified 2 distinct AKI subphenotypes (classes 1 and 2). The long-term risk for MAKE was higher with class 2 (adjusted HR, 1.41 [95% CI, 1.08-1.84]; P=0.01) compared with class 1, adjusting for demographics, hospital level factors, and KDIGO stage of AKI. The higher risk of MAKE among class 2 was explained by a higher risk of long-term chronic kidney disease progression and dialysis. The top variables that were different between classes 1 and 2 included plasma and urinary biomarkers of inflammation and epithelial cell injury; serum creatinine ranked 20th out of the 29 variables for differentiating classes. LIMITATIONS: A replication cohort with simultaneously collected blood and urine sampling in hospitalized adults with AKI and long-term outcomes was unavailable. CONCLUSIONS: We identify 2 molecularly distinct AKI subphenotypes with differing risk of long-term outcomes, independent of the current criteria to risk stratify AKI. Future identification of AKI subphenotypes may facilitate linking therapies to underlying pathophysiology to prevent long-term sequalae after AKI. PLAIN-LANGUAGE SUMMARY: Acute kidney injury (AKI) occurs commonly in hospitalized patients and is associated with high morbidity and mortality. The AKI definition lumps many different types of AKI together, but subgroups of AKI may be more tightly linked to the underlying biology and clinical outcomes. We used 29 different clinical, blood, and urinary biomarkers and applied 2 different statistical algorithms to identify AKI subtypes and their association with long-term outcomes. Both clustering algorithms identified 2 AKI subtypes with different risk of chronic kidney disease, independent of the serum creatinine concentrations (the current gold standard to determine severity of AKI). Identification of AKI subtypes may facilitate linking therapies to underlying biology to prevent long-term consequences after AKI.
引用
- Bhatraju PK, Prince DK, Mansour S, et al. Integrated Analysis of Blood and Urine Biomarkers to Identify Acute Kidney Injury Subphenotypes and Associations With Long-term Outcomes. Am J Kidney Dis. 2023. PMID: 37178093. doi:10.1053/j.ajkd.2023.01.449
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。